RxDoctor Payments DataLook up a doctor →

Ashley Holdridge, DO

Neurology · Whitefish Bay, WINPI 1790003549

Payments from drug & device makers

$367,906in general payments, 2019–2025

Across 737 payments — averaging $499.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$120K
  • Teva Pharmaceuticals USA, Inc.$86K
  • Lundbeck LLC$67K
  • Lilly USA, LLC$38K
  • Amgen$36K
  • Biohaven Pharmaceuticals, Inc.$17K
  • plus $4K from 6 others

What the payments were for

  • Consulting fees$34,2419%
  • Speaking & faculty fees$293,22380%
  • Grants$420%
  • Travel & lodging$29,0768%
  • Food & beverage$11,1533%
  • Education$1720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$367,906 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$79,510
Medicare patients
73
Services billed
11,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant136$191,592
Nurtec OdtRimegepant Sulfate99$148,290
Aimovig AutoinjectorErenumab-Aooe124$104,987
Emgality PenGalcanezumab-Gnlm113$89,370
QuliptaAtogepant61$64,516
Ajovy AutoinjectorFremanezumab-Vfrm29$26,500
Sumatriptan Succinate42$7,126
Tizanidine Hcl75$889
Gabapentin33$713
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine64$607
RizatriptanRizatriptan Benzoate34$589
Chlorzoxazone18$543
Baclofen41$527
Cyclobenzaprine Hcl28$373
Ondansetron OdtOndansetron28$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$120,095$256,108197 claims
PfizerNurtec Odt$19$148,29099 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Wisconsin.

Other neurology in Whitefish Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →